<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Chun J</submitter><funding>NIAID NIH HHS</funding><funding>NIH HHS</funding><pubmed_abstract>The monoclonal antibody L9 mediates high-level protection against malaria in children for up to 6 months in Africa. L9 preferentially binds with high affinity to the NVDP minor repeat on the &lt;i>P. falciparum&lt;/i> circumsporozoite protein (PfCSP). Here, we sought to improve the affinity of L9 to enhance protection against rare strains with two spatially separated minor repeats or a single minor repeat. Site saturation mutagenesis and yeast display-screening identified a panel of affinity-improved variants. &lt;i&gt;In vivo&lt;/i> challenge showed one variant, L9_yd19, to be modestly more potent against a chimeric transgenic &lt;i>Plasmodium&lt;/i> encoding PfCSP with two widely spaced minor repeats from a Kenyan parasite strain, with no loss in potency against the benchmark 3D7 strain with its standard com</pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2025.09.30.679367</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12621802</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Anti-Malaria Antibody Engineering Broadens Recognition Motifs and Reveals New Homotypic Interactions that Enhance Protective Breadth.</pubmed_title><pmcid>PMC12621802</pmcid><funding_grant_id>R01 AI192975</funding_grant_id><funding_grant_id>DP5 OD023118</funding_grant_id><funding_grant_id>R01 AI181684</funding_grant_id><pubmed_authors>Hurlburt NK</pubmed_authors><pubmed_authors>Miura K</pubmed_authors><pubmed_authors>Lee GA</pubmed_authors><pubmed_authors>Teng IT</pubmed_authors><pubmed_authors>Lei H</pubmed_authors><pubmed_authors>Zavala F</pubmed_authors><pubmed_authors>Tripathi P</pubmed_authors><pubmed_authors>Fahad AS</pubmed_authors><pubmed_authors>Zhou T</pubmed_authors><pubmed_authors>Flores-Garcia Y</pubmed_authors><pubmed_authors>DeKosky BJ</pubmed_authors><pubmed_authors>Madan B</pubmed_authors><pubmed_authors>Chun J</pubmed_authors><pubmed_authors>Pancera M</pubmed_authors><pubmed_authors>Idris AH</pubmed_authors><pubmed_authors>Seder RA</pubmed_authors><pubmed_authors>Flynn BJ</pubmed_authors><pubmed_authors>Kwong PD</pubmed_authors></additional><is_claimable>false</is_claimable><name>Anti-Malaria Antibody Engineering Broadens Recognition Motifs and Reveals New Homotypic Interactions that Enhance Protective Breadth.</name><description>The monoclonal antibody L9 mediates high-level protection against malaria in children for up to 6 months in Africa. L9 preferentially binds with high affinity to the NVDP minor repeat on the &lt;i>P. falciparum&lt;/i> circumsporozoite protein (PfCSP). Here, we sought to improve the affinity of L9 to enhance protection against rare strains with two spatially separated minor repeats or a single minor repeat. Site saturation mutagenesis and yeast display-screening identified a panel of affinity-improved variants. &lt;i&gt;In vivo&lt;/i> challenge showed one variant, L9_yd19, to be modestly more potent against a chimeric transgenic &lt;i>Plasmodium&lt;/i> encoding PfCSP with two widely spaced minor repeats from a Kenyan parasite strain, with no loss in potency against the benchmark 3D7 strain with its standard com</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-06-11T03:10:43.32Z</modification><creation>2026-06-11T03:07:52.21Z</creation></dates><accession>S-EPMC12621802</accession><cross_references><pubmed>41256528</pubmed><doi>10.1101/2025.09.30.679367</doi></cross_references></HashMap>